Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma (NCT06667687)

🧪 Interventions in This Study

• ABBV-291 (DRUG)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. For dose escalation (Part 1) only: Participants must have documented diagnosis of B-cell malignancies including (but not limited to) the following, with histology based on criteria established by the World Health Organization (WHO), and measurable disease requiring treatment:
2. Mantle cell lymphoma (MCL);
3. Marginal zone lymphoma (MZL);
4. Waldenstrom macroglobulinemia (WM);
5. Diffuse large b-cell lymphoma (DLBCL) (including: germinal center B-cell type, activated B-cell type, primary cutaneous DLBCL \[leg type\], Epstein-Barr virus-positive (EBV+) DLBCL \[not otherwise specified\], DLBCL associated with chronic inflammation, human herpesvirus 8-positive \[HHV8+\] DLBCL \[not otherwise specified\], B cell lymphoma \[unclassifiable\] with features intermediate between DLBCL and classical Hodgkin lymphoma, high-grade B-cell lymphoma \[not otherwise specified\], high-grade B-cell lymphoma \[with MYC (avian myelocytomatosis viral oncogene homolog) and BCL2 and/or BCL6 rearrangements\], DLBCL arising from follicular lymphoma \[FL\] \[transformed FL\]);
6. FL Grades 1 to 3B;
7. For dose expansion (Part 2) only: Participants must have documented diagnosis of one of the following B-cell malignancies, with histology based on criteria established by the WHO, and measurable disease requiring treatment:
8. Part 2a only: DLBCL (including: germinal center B-cell type, activated B-cell type, primary cutaneous DLBCL \[leg type\], EBV+ DLBCL \[not otherwise specified\], DLBCL associated with chronic inflammation, HHV8+ DLBCL \[not otherwise specified\], B-cell lymphoma \[unclassifiable\] with features intermediate between DLBCL and classical Hodgkin lymphoma, high-grade B-cell lymphoma \[not otherwise specified\], high-grade B-cell lymphoma \[with MYC and BCL2 and/or BCL6 rearrangements\], DLBCL arising from FL \[transformed FL\]);
9. Part 2b only: FL Grades 1 to 3B;
10. Part 2c only: Mantle cell lymphoma;
11. For all participants (Parts 1 and 2):
12. Must be considered relapsed or refractory to, or intolerant of, at least 2 or more prior lines of therapy known to provide a clinical benefit for their condition, and for whom there is no appropriate locally available therapy known to provide clinical benefit (e.g., standard chemotherapy or autologous stem cell transplantation \[ASCT\]).

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (14 Sites)

• Carolina BioOncology Institute /ID# 265259 — Huntersville, North Carolina
• Willamette Valley Cancer Institute and Research Center /ID# 270945 — Eugene, Oregon
• Texas Oncology - Central/South Texas /ID# 270946 — Austin, Texas
• START Mountain Region /ID# 267592 — West Valley City, Utah
• Virginia Cancer Specialists - Fairfax /ID# 265082 — Fairfax, Virginia
• St Vincent's Hospital Melbourne /ID# 261664 — Fitzroy Melbourne, Victoria
• Sir Charles Gairdner Hospital /ID# 268579 — Nedlands, Western Australia
• Hadassah Medical Center-Hebrew University /ID# 261658 — Jerusalem, Jerusalem
• Tel Aviv Sourasky Medical Center /ID# 261659 — Tel Aviv, Tel Aviv
• Aichi Cancer Center /ID# 267471 — Nagoya, Aichi-ken
• National Cancer Center Hospital East /ID# 261775 — Kashiwa-shi, Chiba
• The Cancer Institute Hospital Of JFCR /ID# 267470 — Koto-ku, Tokyo
• The Christie /ID# 267177 — Manchester,
• University Hospitals Plymouth NHS Trust /ID# 267174 — Plymouth,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
• 💵 Compensation indicated: Approximately 165 adult participants with multiple NHL subtypes will be enrolled in the study in sites world wide In the dose escalation phase of the study participants will receive escalating Int...

More studies in Non-Hodgkin's Lymphoma

• Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies — Boston, Massachusetts
• Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO) — Houston, Texas
• PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study — New York, New York
• A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma — Ann Arbor, Michigan
• Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas — Philadelphia, Pennsylvania

Explore by condition: All Non-Hodgkin's Lymphoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.